At close: September 26 at 4:00 PM EDT
After hours: September 26 at 7:59 PM EDT
Key Executives
Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Dr. Benjamin J. Zeskind M.B.A., Ph.D. | Co-Founder, President, CEO & Director | 935.09k | -- | 1983 |
| Mr. Robert J. Carpenter M.B.A., M.S. | Co-Founder & Chair Emeritus | 75.36k | -- | 1946 |
| Dr. Brett M. Hall Ph.D. | Chief Scientific Officer | 905.41k | -- | 1969 |
| Mr. Harold E. Brakewood | Chief Business Officer | 579.77k | -- | 1966 |
| Ms. Mallory Morales CPA | Principal Financial & Accounting Officer, Chief Accounting Officer and Treasurer | -- | -- | 1984 |
| Ms. Paula George CPA | Director of Accounting & Operations and Assistant Corporate Controller | -- | -- | -- |
| Mr. Michael D. Bookman J.D. | Chief Legal Officer & Secretary | -- | -- | 1987 |
| Ms. Leah R. Neufeld | Chief People Officer | -- | -- | 1973 |
| Dr. Peter King Ph.D. | Head of Discovery & VP | -- | -- | -- |
| Dr. Praveen Nair Ph.D. | Head of Translational Pharmacology & VP | -- | -- | -- |
Immuneering Corporation
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 66
Description
Immuneering Corporation, a clinical-stage oncology company, engages in the development of medicines for broad populations of cancer patients. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor currently under Phase 1/2a clinical trial to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 is in Investigational New Drug application to treat solid tumors. Immuneering Corporation was incorporated in 2008 and is based in Cambridge, Massachusetts.
Corporate Governance
Immuneering Corporation’s ISS Governance QualityScore as of September 18, 2024 is 8. The pillar scores are Audit: 7; Board: 7; Shareholder Rights: 7; Compensation: 9.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.
Upcoming Events
Upcoming Events Information Not Available
Recent Events
Related Tickers
XCUR Exicure, Inc.
3.8100
+4.10%
NBY NovaBay Pharmaceuticals, Inc.
0.7300
+5.80%
GLMD Galmed Pharmaceuticals Ltd.
7.33
+3.39%
CERO CERo Therapeutics Holdings, Inc.
0.0943
-5.70%
CAPR Capricor Therapeutics, Inc.
9.99
-3.38%
BDTX Black Diamond Therapeutics, Inc.
4.4100
+5.00%
PRTG Portage Biotech Inc.
7.17
+2.87%
WVE Wave Life Sciences Ltd.
8.02
-10.99%
ELYM Eliem Therapeutics, Inc.
5.0000
-9.09%
BCTX BriaCell Therapeutics Corp.
0.7149
-5.93%